Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book

被引：6
|
作者：
Santos, Raul D. [1 ,2 ]
Rocha, Viviane Z. [1 ]
机构：
[1] Univ Sao Paulo, Med Sch Hosp, Heart Inst InCor, Lipid Clin, Av Dr Eneas C Aguiar 44, BR-05403900 Sao Paulo, Brazil
[2] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷 / 02期
关键词：
EVOLOCUMAB;
D O I：
10.1093/eurheartj/ehac656
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'Inclisiran and cardiovascular events: a patient-level analysis of phase III trials, by K.K. Ray et al., https://doi.org/10. 1093/eurheartj/ehac594.
引用
收藏
页码：139 / 141
页数：3
相关论文
共 50 条
  • [1] PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
    David Preiss
    Marion Mafham
    Diabetologia, 2017, 60 : 381 - 389
  • [2] PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
    Preiss, David
    Mafham, Marion
    DIABETOLOGIA, 2017, 60 (03) : 381 - 389
  • [3] Limitations of cholesterol lowering with PCSK9 inhibitors
    Thompson, Gilbert
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (04): : 241 - 243
  • [4] New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide
    Landmesser, Ulf
    Makhmudova, Umidakhon
    CIRCULATION, 2023, 148 (02) : 159 - 161
  • [5] PCSK9 inhibition: a new player in cholesterol-lowering therapies?
    David Preiss
    Colin Baigent
    Nature Reviews Nephrology, 2017, 13 : 450 - 451
  • [6] PCSK9 inhibition: a new player in cholesterol-lowering therapies?
    Preiss, David
    Baigent, Colin
    NATURE REVIEWS NEPHROLOGY, 2017, 13 (08) : 451 - 452
  • [7] The PCSK9 story
    Abifadel, Marianne
    Boileau, Catherine
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1341 - 1342
  • [8] A cholesterol-lowering VLP vaccine that targets PCSK9
    Crossey, Erin
    Amar, Marcelo J. A.
    Sampson, Maureen
    Peabody, Julianne
    Schiller, John T.
    Chackerian, Bryce
    Remaley, Alan T.
    VACCINE, 2015, 33 (43) : 5747 - 5755
  • [9] PCSK9 and atherosclerosis: Beyond LDL-cholesterol lowering
    Cariou, Bertrand
    Ding, Zufeng
    Mehta, Jawahar L.
    ATHEROSCLEROSIS, 2016, 253 : 275 - 277
  • [10] Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk
    Santulli, Gaetano
    Jankauskas, Stanislovas S.
    Gambardella, Jessica
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2021, 7 (03) : E11 - E12
12345